CIENCIASMEDICASNEWS

sábado, 1 de agosto de 2026

One dose of new gene therapy could reduce tau protein throughout brain. Written byAllison Whitten, PhD

One dose of new gene therapy could reduce tau protein throughout brain Voyager Therapeutics’ promising toxicology data in non-human primates suggests their proprietary capsid technology could deliver long-lasting results in Alzheimer’s disease. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/one-dose-of-new-gene-therapy-could-reduce-tau-protein-throughout-brain-17378 Tau-targeting therapies focus on ridding the brain of the toxic tau protein that wreaks havoc in neurodegenerative diseases like Alzheimer’s disease (AD). Drugs currently under investigation to target tau include immunotherapies, small molecule tau inhibitors, antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs) and gene therapy. Gene therapy options, in particular, have the exciting potential to offer broad and durable reductions in tau in just one dose.

June M&A recap: Three deals, three billion-dollar stories. Written byAndrea Corona

June M&A recap: Three deals, three billion-dollar stories The science being built right now in discovery labs is what acquirers are already looking for. Written byAndrea Corona https://www.drugdiscoverynews.com/june-m-a-recap-three-deals-three-billion-dollar-stories-17401 June delivered one of the most concentrated bursts of biopharma dealmaking in years. Three acquisitions exceeding $10 billion each landed in a single week at the end of the month, capping a first half of 2026 that has already produced 33 deals worth $1 billion or more and $134 billion in total value — surpassing all of 2025 in roughly half the time.

What cells can teach us about discovering better drugs. Written byBree Foster, PhD

What cells can teach us about discovering better drugs By tracking how cells respond to hundreds of thousands of compounds, Soley Therapeutics aims to discover medicines for complex diseases where traditional target-based approaches often fall short. Written byBree Foster, PhD https://www.drugdiscoverynews.com/what-cells-can-teach-us-about-discovering-better-drugs-17398 Modern drug discovery has become increasingly adept at identifying promising therapeutic targets. Advances in genomics, proteomics, and AI now allow researchers to sift through vast biomedical datasets to pinpoint proteins and pathways most likely to influence disease. Yet despite these advances, most drug candidates still fail in the clinic, often because the underlying biology proves more complex than anticipated.

Precision medicine needs more precise diagnostics. Written byBree Foster, PhD

Precision medicine needs more precise diagnostics Wobble Genomics is using long-read RNA sequencing to reveal the molecular signals that determine whether a cancer treatment will work. Written byBree Foster, PhD https://www.drugdiscoverynews.com/precision-medicine-needs-more-precise-diagnostics-17397 The goal of precision oncology is to deliver the right cancer treatment to the right patient at the right dose and at the right time. Advances in genomics have made this a reality, giving rise to targeted therapies, antibody-drug conjugates, and immunotherapies that exploit the unique molecular features of individual tumors. Yet despite increasingly sophisticated medicines, many patients still fail to respond as predicted.

FDA panel backs unapproved peptides despite safety concerns Written byDDN editorial team

FDA panel backs unapproved peptides despite safety concerns Positive results for GLP-1 drugs in alcohol use disorder, a new collaboration to advance in vivo CAR T therapies, Phase 3 readouts in oncology, rare disease, and vitiligo, and more led the news this week. Written byDDN editorial team https://www.drugdiscoverynews.com/fda-panel-backs-unapproved-peptides-despite-safety-concerns-17408 An FDA advisory committee has voted to recommend adding six unapproved peptides to the agency's 503A bulk compounding list, a move that could eventually allow compounding pharmacies to produce the substances for patient-specific prescriptions despite ongoing concerns over their safety and efficacy. In closely split votes, the panel backed BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax for a range of proposed uses including wound healing, ulcerative colitis, weight loss, migraines, pain, and insomnia, while rejecting emideltide for opioid withdrawal and sleep disorders. FDA scientific reviewers had advised against adding any of the peptides, citing a lack of robust clinical evidence and unanswered safety questions, but supporters argued that regulated compounding would provide a safer alternative to the growing grey market, where the substances are widely sold as research-grade products despite not being approved for human use. The recommendation does not immediately legalize compounded versions of the peptides, with the FDA now needing to decide whether to initiate the rulemaking process to add them to the 503A bulk compounding list, a step that could take a year or more. – Bree Foster